Intellia Therapeutics, Inc. reported a net loss of $412.7 million for the fiscal year ending December 31, 2025, a decrease from the $519.0 million loss recorded in the previous year. The company's collaboration revenue increased by $9.8 million to $67.7 million, primarily driven by a rise in cost reimbursements from its partnership with Regeneron Pharmaceuticals, Inc. and revenue from the termination of a collaboration agreement with SparingVision SAS. Operating expenses decreased to $508.7 million from $592.1 million, largely due to reduced research and development costs, which fell by $77.5 million, reflecting a strategic focus on high-value programs and a workforce reduction.
Research and development expenses for the year were $388.9 million, with notable increases in external costs for the development of lead product candidates, nexiguran ziclumeran (nex-z) and lonvoguran ziclumeran (lonvo-z). The company reported a significant decrease in employee-related expenses and stock-based compensation, attributed to workforce reductions and lower grant values. General and administrative expenses also saw a slight decline, primarily due to reduced stock-based compensation, although costs related to building out commercial infrastructure increased.
Intellia's cash, cash equivalents, and marketable securities totaled $605.1 million as of December 31, 2025. The company anticipates that these resources, along with collaboration funding, will support operations into the second half of 2027. The firm has entered into an at-the-market offering agreement, allowing it to raise additional capital as needed, although it acknowledges the potential for dilution of existing shareholders.
The company is currently focused on advancing its lead product candidates, which are in Phase 3 clinical trials. Nex-z is under a clinical hold by the FDA, which was lifted for the MAGNITUDE-2 trial, while lonvo-z is preparing for a commercial launch anticipated in the first half of 2027. Intellia's future success hinges on its ability to navigate regulatory challenges, secure additional funding, and effectively commercialize its product candidates, all while managing the risks associated with the rapidly evolving biotechnology landscape.
About Intellia Therapeutics, Inc.
Intellia Therapeutics is a leading clinical-stage biotech company specializing in CRISPR-based gene editing therapies. Its core focus is developing in vivo and ex vivo treatments for genetic diseases, including rare disorders like ATTR amyloidosis and hereditary angioedema, as well as cancer and autoimmune conditions. The company leverages proprietary technologies, strategic collaborations, and a broad IP portfolio to deliver potentially curative, precision medicines.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.